Can Global Policies Boost Biosimilar Adoption Work in the US?
On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars...
top of page
Subscriber login:
SUBMIT
Remember me
Search
Nov 11
A Guide to Patient Financial Assistance Programs
Patient financial assistance programs are implemented by drug manufacturers to help manage the cost of their drugs for patients.
Nov 11
Biosimilar Interchangeability: FDA Designation, Marketing Exclusivity, Guidance, and Future Trends
Biologics are regulated by the FDA and are approved under the 351(a) pathway with a Biologics License Application (BLA).
Nov 11
Understanding Limited Distribution Networks
Understanding which drugs are distributed through specialty pharmacies can be helpful for pharmacies, manufacturers, and payers
Oct 14
Why Haven't More Patients Been Treated With the Gene Therapies for Sickle Cell Disease? | AMCP Nexus 2024
Uncover the reasons behind the limited adoption of gene therapies for sickle cell disease at the AMCP Nexus 2024.
Sep 3
Can Outcomes-Based Agreements Work for Weight Loss Drugs?
Outcomes-based agreements can take away clinical uncertainties, so payers have a guarantee that they're not spending money on something...
Sep 2
Upcoming Biosimilars and the Impact of IRA: Key Takeaways From Jeffrey Casberg
Jeffrey Casberg discusses key upcoming biosimilars and specialty drugs, the impact of the Inflation Reduction Act on drug pricing, and...
Jul 20
Biosimilars in America: Overcoming Barriers and Maximizing Impact
issues affecting payer uptake and provider adoption of biosimilars in the US, such as economic considerations, clinical evidence, and market
Jul 13
IPD Analytics' Jeffrey Casberg Discusses Recent Biosimilar Approvals
Jeffrey Casberg, MS, RPh, senior vice president of pharmacy at IPD Analytics, discussed the FDA approvals of new drugs and pricing.
Jun 29
Jeffrey Casberg of IPD Analytics Gives Insight on Specialty Drugs in the Pipeline
In an interview with Jeffrey Casberg, MS, RPh, he discusses 3 promising specialty drugs coming through the pipeline.
Jun 23
IPD Analytics' Jeffrey Casberg Says IRA, PBM Legislation Reshape US Drug Costs
Jeffrey Casberg, RPh, MS, from IPD Analytics, explains why he believes policy changes and market forces are impacting the cost of drugs,...
May 30
Key Pharmaceutical Pipeline Developments: Insights from Industry Experts
Learn about promising drugs currently in the pharmaceutical pipeline and the impact of FDA interventions from IPD presenters.
May 15
Additional Price Cuts to Insulin are on the Way
Several drug manufacturers have announced price cuts on commonly prescribed insulin products. By Brock Bizzell and David Baker | Original...
May 11
Jeffrey Casberg Predicts Generic, Biosimilar Competition in the Pharmaceutical Market
Jeffrey Casberg, RPh, MS, examines upcoming generic and biosimilar competition in the pharmaceutical industry, showcasing certain drugs...
Apr 21
AMCP 2024: Key Takeaways From Leading Speakers
IPD Analytics speaks about key takeaways from the AJMC 2024 Annual Conference
Apr 17
Introduction to Digital Therapeutics and Potential Payer Management
This article explains the ins and outs of digital therapeutics.
Apr 17
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
IPD presents at the AMCP 2024 annual meeting discussing the current promise and future potential of gene and cell therapies.
Apr 17
Potential Generics Could Lower Prices for Oncology, Cardiovascular Drugs | AMCP 2024
IPD Analytics LLC. discusses the up to 50 generics that could be approved this year, including Victoza to treat patients with diabetes.
Apr 11
Payers Recognize the Benefits, but Still See Weight Loss Drugs through a Cost Lens
Jeffrey Casberg of IPD Analytics LLC, talks about how payers are thinking about weight-loss drugs.
Mar 21
Why Every Hospital Needs a Chief Pharmacy Officer in the C-Suite
A CPO in the C-suite determines how a health system can move from a cost center to a revenue center with healthy operating margins
Dec 27, 2023
2024 Prediction from Jeffrey Casberg, M.S., RPh
Casberg is Vice President of Clinical Pharmacy at IPD Analytics LLC and a member of the Managed Healthcare Executive editorial advisory...
Dec 19, 2023
Biosimilars are Ascendant
Explore the evolving landscape of biosimilars in the US market, from legislative influences to industry challenges, with expert insights.
Nov 6, 2023
Amgen Confirms US Aflibercept Filing As Regeneron Awaits Biocon Trial Fate
Amgen has thrown its hat in the ring to launch a US biosimilar to Regeneron’s Eylea eye-disease blockbuster.
Oct 12, 2023
Specialty Generic Market to Exceed $40 Billion by 2027
The U.S. market for specialty generic drugs hit $23 billion in 2021, and is expected to reach nearly $43 billion by 2027, driven by the...
bottom of page